A new trading day began on Tuesday, with Vera Therapeutics Inc (NASDAQ: VERA) stock price up 4.48% from the previous day of trading, before settling in for the closing price of $21.64. VERA’s price has ranged from $18.53 to $51.61 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 4.49% over the past five years. Meanwhile, its annual earnings per share averaged -55.42%. With a float of $48.53 million, this company’s outstanding shares have now reached $63.82 million.
Vera Therapeutics Inc (VERA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Vera Therapeutics Inc is 23.96%, while institutional ownership is 89.01%. The most recent insider transaction that took place on Jun 23 ’25, was worth 4,369,676. In this transaction Director of this company bought 209,393 shares at a rate of $20.87, taking the stock ownership to the 3,569,522 shares. Before that another transaction happened on Jun 24 ’25, when Company’s Director bought 40,607 for $22.35, making the entire transaction worth $907,635. This insider now owns 3,596,593 shares in total.
Vera Therapeutics Inc (VERA) Latest Financial update
In its latest quarterly report, released on 9/30/2024, the company reported earnings of -0.85 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -55.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.39% during the next five years compared to 4.49% growth over the previous five years of trading.
Vera Therapeutics Inc (NASDAQ: VERA) Trading Performance Indicators
Here are Vera Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 16.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.58, a number that is poised to hit -1.14 in the next quarter and is forecasted to reach -4.51 in one year’s time.
Technical Analysis of Vera Therapeutics Inc (VERA)
Vera Therapeutics Inc (NASDAQ: VERA) saw its 5-day average volume 2.03 million, a positive change from its year-to-date volume of 1.35 million. As of the previous 9 days, the stock’s Stochastic %D was 30.58%.
During the past 100 days, Vera Therapeutics Inc’s (VERA) raw stochastic average was set at 28.20%, which indicates a significant decrease from 56.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.11 in the past 14 days, which was lower than the 1.22 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.17, while its 200-day Moving Average is $29.27. Nevertheless, the first resistance level for the watch stands at $23.05 in the near term. At $23.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $24.18. If the price goes on to break the first support level at $21.91, it is likely to go to the next support level at $21.21. The third support level lies at $20.77 if the price breaches the second support level.
Vera Therapeutics Inc (NASDAQ: VERA) Key Stats
With a market capitalization of 1.44 billion, the company has a total of 63,824K Shares Outstanding. Currently, annual sales are 0 K while annual income is -152,150 K. The company’s previous quarter sales were 0 K while its latest quarter income was -76,530 K.
